NICE

Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury (interventional procedures consultation) (30th June 2008)
The National Institute for Health and Clinical Excellence is examining therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury and will publish guidance on its safety and efficacy to the NHS in England, Wales, Scotland and Northern Ireland. The Institute's Interventional Procedures Advisory Committee has considered the available evidence and the views of Specialist Advisers, who are consultants with knowledge of the procedure. The Advisory Committee has made provisional recommendations about therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury. Closing date for comments is 28th July 2008.
Click here for the Consultation

Transabdominal artificial bowel sphincter implantation for faecal incontinence (interventional procedures consultation) (30th June 2008)
The National Institute for Health and Clinical Excellence is examining transabdominal artificial bowel sphincter implantation for faecal incontinence and will publish guidance on its safety and efficacy to the NHS in England, Wales, Scotland and Northern Ireland. The Institute's Interventional Procedures Advisory Committee has considered the available evidence and the views of Specialist Advisers, who are consultants with knowledge of the procedure. The Advisory Committee has made provisional recommendations about transabdominal artificial bowel sphincter implantation for faecal incontinence. Closing date for comments is 28th July 2008.
Click here for the Consultation

Lung cancer (non-small cell) - erlotinib (appraisal consultation) (4th July 2008)
The Department of Health and the Welsh Assembly Government have asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a single technology appraisal (STA) of erlotinib and provide guidance on its use to the NHS in England and Wales. The Appraisal Committee has had its fifth meeting to consider both the evidence submitted by the manufacturer and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of erlotinib. Closing date for comments is 25th July 2008.
Click here for the Consultation
Click here for the Evaluation Report

Breast cancer (advanced or metastatic) - lapatinib (appraisal consultation) (7th July 2008)
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a single technology appraisal (STA) of lapatinib (in combination with capecitabine) and provide guidance on its use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted by the manufacturer and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of lapatinib. Closing date for comments is 28th July 2008.
Click here for the Consultation
Click here for the Evaluation Report

Osteoporosis - secondary prevention including strontium ranelate: final appraisal determination (8th July 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Closing date for comments is 21st July 2008.
Final Appraisal Determination
Expert comments on the ACD
Consultee and commentator comments on the ACD
Response to consultee, commentator and public comments on the ACD

Osteoporosis - primary prevention: final appraisal determination (8th July 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Closing date for comments is 21st July 2008.
Final Appraisal Determination
Expert comments on the ACD
Consultee and commentator comments on the ACD
Response to consultee, commentator and public comments on the ACD

Sedation in infants, children and young people: scope consultation (11th July 2008)
NICE have been asked to develop a clinical practice guideline on Sedation in infants, children and young people for use in the NHS in England, Wales and Northern Ireland. The draft scope defines what aspects of care the guideline will cover and to whom it will apply. Registered stakeholders for the Sedation in infants, children and young people guideline are invited to submit comments on the scope and may suggest clinical questions that could be answered in the guideline. Closing date for comments is 8th August 2008.
Click here for Draft Scope
Click here for Comments Proforma

Latest Implementation Tools (9th July 2008)

Perioperative hypothermia (inadvertent)
Click here for Audit Support
Click here for Implementation Advice